[Use of aspirin for primary prevention of cardiovascular events in diabetic patients--is it justified?].
Benhamou
Y
Y
Lévesque
H
H
D001241:Aspirin / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control; D003324:Coronary Artery Disease / Q000209:etiology / Q000517:prevention & control*; D048909:Diabetes Complications / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D015201:Meta-Analysis as Topic; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011322:Primary Prevention / Q000379:methods*; D012307:Risk Factors
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D001241:Aspirin